5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX

The article argues Eli Lilly (LLY) is a better buy than SpaceX after SpaceX’s IPO priced at $135 and surged nearly 20% on day one, though shares have since slipped to about $150. For Lilly, weight-loss drugs (Mounjaro + Zepbound) drove more than $12B in the latest quarter, and the company launched oral weight-loss drug Foundayo with additional late-stage candidates. The piece highlights Lilly’s profitability track record, a roughly 33x forward earnings valuation (down from >40x earlier this year), and a $6.92 dividend (~0.5% yield), contrasting with SpaceX’s $4.9B loss and very high valuation.

Analysis

This reads as a vote for durable cash-flow compounding over capital-intensive optionality. For LLY, the market mechanism is less "drug story" and more a re-rating debate: can a high-teens growth franchise sustain a premium multiple if obesity supply normalizes and payers keep tightening access? If prescription momentum stays intact, the stock can still work, but at this valuation the burden of proof shifts to margin durability and pipeline conversion, not just unit growth.

The second-order effect is competitive: every incremental share gain by LLY pressures NVO, compounding the risk that the obesity market becomes a pricing war rather than a pure volume expansion story. Watch for formulary changes, compounding/telehealth leakage, and oral/next-gen launch cadence over the next 1-3 quarters; those are the real catalysts, not the promotional framing. If gross-to-net or access deteriorates, the multiple can compress quickly even with headline revenue growth.

For SPCX, the relevant lesson is post-IPO exhaustion risk in any long-duration, capex-heavy growth asset: early holders often monetize first and ask questions later. If the stock is liquid, the highest-risk window is the next 1-2 months, when lock-up, index inclusion, and profit-taking can overwhelm narrative demand. The contrarian take is that the market may be overpaying for scarcity and underpricing execution risk; the article is implicitly telling you that quality-free-cash-flow matters more than venture-style upside right now.

Key Decisions for Investors

• Long LLY / short NVO for 1-3 months into obesity-prescription data and quarterly updates; thesis works if LLY share gains persist and NVO margin guidance gets revised lower. Falsify on any evidence of LLY access pressure or slowing script growth.
• Buy LLY on pullbacks only; avoid chasing after headline-driven strength. Use a 4-8 week entry window and require a reset toward prior breakout support before adding risk.
• If SPCX is liquid and borrow is reasonable, fade the post-IPO move via a small put spread or short against a basket of profitable large-cap growth names. Best setup is 2-6 weeks after initial euphoria when lock-up/valuation math matters most.
• Relative-value long LLY vs short XBI as a cleaner way to express 'profitable growth over speculative biotech' if you want sector exposure without idiosyncratic IPO risk. Exit if XBI starts outperforming on a broad risk-on biotech tape.